E1	Condition:T1 Name:T2 Severity:T12
E2	Temporal-Connection:T5 Arg:E7 Arg2:E8
E3	Eq-Comparison:T7 Temporal-Period:T8
E4	Or:T10 Arg:T3 Arg2:T9
E5	Modifier:T11 Modifies:T2
E6	And:T13 Arg:T9 Arg2:E1
E7	Study:T14
E8	Procedure:T6
E9	Drug:T15 Name:T16
E10	Drug:T17 Name:T4
E11	Contraindication:T18 Contraindicates:E10
E12	Procedure:T19 Temporality:E3
E13	Drug:T20 Name:T21
T1	Condition 98 114	plaque psoriasis
T2	Condition-Name 98 114	plaque psoriasis
T3	Life-Stage-And-Gender 25 33	Children
T5	Temporal-Connection 121 126	Prior
T7	Eq-Comparison 506 511	prior
T8	Eq-Temporal-Period 506 511	prior
T9	Life-Stage-And-Gender 38 49	adolescents
T10	Or 34 37	and
T11	Modifier 73 90	pediatric chronic
T12	Severity 91 97	severe
T13	And 50 53	who
T14	Study 151 156	study
T6	Procedure 169 178	treatment
T15	Drug 158 168	adalimumab
T16	Drug-Name 158 168	adalimumab
T17	Drug 432 442	adalimumab
T4	Drug-Name 432 442	adalimumab
T18	Contraindication 412 428	contraindication
T19	Procedure 512 521	treatment
T20	Drug 527 537	adalimumab
T21	Drug-Name 527 537	adalimumab
A1	Life-Stage-And-Gender-Type T3 child
A3	Eq-Temporal-Period-Value T8 past
A4	Life-Stage-And-Gender-Type T9 child
A5	Severity-Value T12 severe
A2	Temporal-Connection-Type-Value E2 before
R1	Using Arg1:E8 Arg2:E9
R2	Using Arg1:E12 Arg2:E13